| MS | CT | mAb-CT | mAb-CT/CT |
|---|---|---|---|
| Oncology | 82 | 32 | 39.0% |
| Haematology | 34 | 14 | 41.2% |
| Neurology | 24 | 8 | 33.3% |
| Nephrology | 17 | 2 | 11.8% |
| Digestive | 13 | 5 | 38.5% |
| Pneumology | 12 | 0 | 0% |
| Dermatology | 9 | 7 | 77.8% |
| Infectious diseases | 8 | 0 | 0% |
| Intensive care | 7 | 1 | 14.3% |
| Rheumatology | 6 | 5 | 83.3% |
| Neuropsychology | 5 | 2 | 40% |
| Internal medicine | 4 | 1 | 25% |
| Cardiology | 4 | 2 | 50% |
| Endocrinology | 1 | 0 | 0% |
Total CT: 226; total mAb-CT: 79 (34.9%) mAb-CT by department/total mAb-CT: oncology 40.51%; haematology 17.72%; neurology 10.13%; dermatology 8.86%; digestive 6.33%; rheumatology 6.33%; nephrology 2.53%; neuropsychology 2.53%; cardiology 2.53%; intensive care 1.27%; internal medicine 1.27%; endocrinology 0%; pneumology 0%; infectious diseases 0%. CT-mAb phase: I 7 (8.86%); II 18 (22.78%); III 51 (64.56%); IV 3 (3.80%).